Synairgen Ltd formerly known as Synairgen PLC is a United Kingdom-based company, which is a respiratory drug discovery and development company. Its specialist respiratory biotech company primary focus is developing investigative inhaled interferon beta for the treatment of severe viral lung infections as potentially the broad-spectrum antiviral treatment delivered directly into the lungs.

Employees

Sector

Biotechnology & Medical Research

More about the company

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

Market Cap	817.93 1.11K 957.46 894.94 1.54K 105K 1.57K 10.49K 4.12K 52.77K 4.15K 4.06K 176K	P/E 2023	-0.94x	P/E 2024	-0.67x
Enterprise Value	-4.55M -6.16M -5.33M -4.98M -8.58M -587M -8.71M -58.42M -22.92M -294M -23.12M -22.61M -978M	EV / Sales 2023	-	EV / Sales 2024	-
Free-Float	17.82%	Yield 2023 *	-	Yield 2024	-

04-01	Synairgen Limited Announces Termination of John Bradshaw as Director, Effective March 31, 2026	CI
04-01	Synairgen Limited Announces Termination of Director Martin Patrick Murphy, Effective March 31, 2026	CI
02-26	Synairgen Limited Announces Its Decision to Terminate the Ongoing Global Phase 2 Clinical Study	CI
12-08	Synairgen Limited Announces First Patient Dosed in the Global Phase 2 Invent Clinical Study	CI
25-10-01	Synairgen plc Reports Earnings Results for the Full Year Ended December 31, 2024	CI
25-09-30	Synairgen plc Auditor Raises 'Going Concern' Doubt	CI
25-09-04	Synairgen plc Provides Business Update	CI
25-05-16	Synairgen plc Announces Chief Executive Officer Changes	CI
25-05-16	Synairgen plc Announces Transition of Mark Parry-Billings to Executive Chairman, Effective 1 July 2025	CI
25-05-16	Synairgen plc Announces Step Down of Joseph Colliver as Chief Financial Officer	CI
25-05-01	Synairgen plc Announces Appointment of John Bradshaw to the Board as an Independent Non-Executive Director and Chair of the Audit Committee, Effective 1 May 2025	CI

Manager	Title	Age	Since
Joseph Colliver CEO	Chief Executive Officer	46	2025-06-30
Andy Lee DFI	Director of Finance/CFO	-	-
Marcin Mankowski CTO	Chief Tech/Sci/R&D Officer	-	2023-10-02

Director	Title	Age	Since
Joseph Colliver BRD	Director/Board Member	46	2023-11-05
Mark Parry-Billings CHM	Chairman	-	2024-10-09
Martin Murphy BRD	Director/Board Member	57	2025-01-15

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SYNAIRGEN PLC	-.--%	-.--%	-	-	110K
LONZA GROUP AG	+1.29%	+3.09%	+6.43%	+18.53%	49.47B
REVOLUTION MEDICINES, INC.	+0.89%	+10.37%	+491.34%	+598.75%	43.97B
BEONE MEDICINES AG	+3.08%	+13.60%	+24.57%	+78.98%	39.6B
IQVIA HOLDINGS INC.	+1.38%	+2.97%	+34.54%	+10.66%	39.29B
CELLTRION, INC.	+0.85%	+7.66%	+21.22%	+48.78%	32.43B
ASCENDIS PHARMA A/S	+0.08%	+4.80%	-	-	16.84B
MEDPACE HOLDINGS, INC.	+1.99%	+4.39%	+38.70%	+126.93%	16.49B
EUROFINS SCIENTIFIC SE	+0.34%	+2.76%	+5.39%	+20.43%	14.01B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+3.56%	+19.13%	+86.23%	+28.36%	12.77B
Average	+1.35%	+7.32%	+88.55%	+116.43%	29.43B
Weighted average by Cap.	+1.48%	+7.06%	+107.88%	+141.57%

Synairgen plc Stock Cinnober Boat

Stocks

SNG

GB00B0381Z20

Biotechnology & Medical Research

Valuation: Synairgen plc

Latest news : Synairgen plc

Managers and Directors: Synairgen plc

Other Biotechnology & Medical Research

Financials

Company Profile

	2023	2024
Net sales	-	-
Net income	-8.41M -11.37M -9.84M -9.2M -15.84M -1.08B -16.09M -108M -42.33M -542M -42.69M -41.76M -1.81B	-6.81M -9.21M -7.97M -7.45M -12.83M -878M -13.04M -87.39M -34.29M -439M -34.58M -33.83M -1.46B
Net Debt	-12.02M -16.25M -14.07M -13.15M -22.64M -1.55B -23M -154M -60.5M -775M -61.01M -59.68M -2.58B	-4.55M -6.16M -5.33M -4.98M -8.58M -587M -8.72M -58.43M -22.93M -294M -23.12M -22.62M -979M